Miodia (Cyclobenzaprine)

Cyclobenzaprine, the active ingredient in Miodia, is a centrally acting muscle relaxant presented as an oral dosage form for oral use. It is indicated for the relief of muscle spasm associated with acute musculoskeletal conditions in adult patients and is formulated to provide consistent systemic exposure across the European Union market.

GNH USA supplies Miodia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across EU and global markets.

Cyclobenzaprine is used to manage muscle spasm and related conditions within the musculoskeletal system.

Muscle spasm: reduces pain and stiffness associated with acute skeletal muscle conditions. Acute low back pain: alleviates muscle tightness contributing to low back discomfort. Neck strain: helps relax cervical musculature and improve range of motion.

Cyclobenzaprine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness - Dry mouth - Dizziness - Fatigue

Serious or Rare Side Effects: - Cardiac arrhythmia - Severe allergic reaction (anaphylaxis) - Psychosis or hallucinations

When prescribing cyclobenzaprine, clinicians should consider several safety measures.

Assess renal and hepatic function: adjust use in patients with significant impairment. Avoid concurrent use with MAO inhibitors: discontinue MAOIs at least 14 days before starting. Monitor for signs of sedation: caution when operating machinery or driving. Use cautiously in elderly: increased sensitivity to CNS effects. Store at ambient temperature: keep in original container, protect from moisture and heat.

Cyclobenzaprine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - CNS depressants (e.g., opioids, benzodiazepines): additive sedation and respiratory depression. - Anticholinergic agents: heightened anticholinergic burden.

Moderate Interactions (Monitor Closely): - Cytochrome P450 1A2 inhibitors (e.g., fluvoxamine): may increase cyclobenzaprine levels. - CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce efficacy. - Serotonergic drugs (e.g., SSRIs): monitor for serotonin syndrome.